Private equity deals in Asia rose to 129, driven by brain tech and surgical robotics
Asia-Pacific healthcare private equity activity nearly doubled this year as investors focus on advanced medical technology.
The number of healthcare private equity funds participating in Asia-Pacific transactions reached 129 in the first half of the year. This count represents an increase from 66 one year earlier, based on data released by Bain & Company. Despite this rise in deal frequency, total disclosed transaction value globally fell 18 per cent to US$51 billion during the same period. Asian family offices are directing significant capital toward specific technologies including brain-computer interfaces and surgical robotics. William Chow, deputy group CEO of Raffles Family Office, noted that the volume of deals involving these technologies has increased significantly compared to two years ago. He stated that a structural demand for improved surgery exists due to an ageing population in Asia. Charles Hu, founder of Ryoden Medical Holdings, added that artificial intelligence is now being applied to clinical use to enhance surgical workflows rather than just drug discovery. At the MedTech World Asia conference in Hong Kong, he emphasized these areas as critical for investor interest.
